CN101469350A - 一种前列腺癌症早期的综合检测试剂盒及检测方法和应用 - Google Patents
一种前列腺癌症早期的综合检测试剂盒及检测方法和应用 Download PDFInfo
- Publication number
- CN101469350A CN101469350A CNA2008100422597A CN200810042259A CN101469350A CN 101469350 A CN101469350 A CN 101469350A CN A2008100422597 A CNA2008100422597 A CN A2008100422597A CN 200810042259 A CN200810042259 A CN 200810042259A CN 101469350 A CN101469350 A CN 101469350A
- Authority
- CN
- China
- Prior art keywords
- hybridization
- prostate
- test kit
- gene
- kit according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 44
- 201000001514 prostate carcinoma Diseases 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 19
- 238000009396 hybridization Methods 0.000 claims abstract description 41
- 239000000523 sample Substances 0.000 claims abstract description 34
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 239000000758 substrate Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 238000012360 testing method Methods 0.000 claims description 19
- 239000003550 marker Substances 0.000 claims description 12
- 238000011065 in-situ storage Methods 0.000 claims description 10
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 6
- 230000002285 radioactive effect Effects 0.000 claims description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 239000012747 synergistic agent Substances 0.000 claims description 5
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 4
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 4
- 229960005156 digoxin Drugs 0.000 claims description 4
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 229930003756 Vitamin B7 Natural products 0.000 claims description 3
- 239000011735 vitamin B7 Substances 0.000 claims description 3
- 235000011912 vitamin B7 Nutrition 0.000 claims description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- 238000003149 assay kit Methods 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 24
- 206010060862 Prostate cancer Diseases 0.000 abstract description 23
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000007901 in situ hybridization Methods 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 238000013016 damping Methods 0.000 description 39
- 239000012530 fluid Substances 0.000 description 39
- 239000007788 liquid Substances 0.000 description 35
- 206010028980 Neoplasm Diseases 0.000 description 22
- 201000011510 cancer Diseases 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 235000011194 food seasoning agent Nutrition 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 210000002249 digestive system Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000002059 diagnostic imaging Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- VOZKAJLKRJDJLL-UHFFFAOYSA-N 2,4-diaminotoluene Chemical compound CC1=CC=C(N)C=C1N VOZKAJLKRJDJLL-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000227135 Atrina Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000882982 Homo sapiens CDK5 regulatory subunit-associated protein 3 Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 241000973497 Siphonognathus argyrophanes Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- -1 developer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
序号 | 杂交探针PSA基因 | 杂交探针PCADM-1基因 | 结果 |
第一种 | 表达 | 表达 | 前列腺癌 |
第二种 | 不表达 | 表达 | 前列腺癌 |
第三种 | 表达 | 不表达 | 前列腺炎症疾病或前列腺增生或假阴性 |
第四种 | 不表达 | 不表达 | 正常 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100422597A CN101469350B (zh) | 2008-08-29 | 2008-08-29 | 一种前列腺癌症早期的综合检测试剂盒及检测方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100422597A CN101469350B (zh) | 2008-08-29 | 2008-08-29 | 一种前列腺癌症早期的综合检测试剂盒及检测方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101469350A true CN101469350A (zh) | 2009-07-01 |
CN101469350B CN101469350B (zh) | 2011-09-14 |
Family
ID=40827155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100422597A Active CN101469350B (zh) | 2008-08-29 | 2008-08-29 | 一种前列腺癌症早期的综合检测试剂盒及检测方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101469350B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102443641A (zh) * | 2011-12-19 | 2012-05-09 | 苏州福英基因科技有限公司 | 各种癌症病理演变前期microrna-16水平原位杂交检测试剂盒及检测方法和应用 |
-
2008
- 2008-08-29 CN CN2008100422597A patent/CN101469350B/zh active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102443641A (zh) * | 2011-12-19 | 2012-05-09 | 苏州福英基因科技有限公司 | 各种癌症病理演变前期microrna-16水平原位杂交检测试剂盒及检测方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101469350B (zh) | 2011-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101469351B (zh) | 一种前列腺癌症早期诊断、转移、复发的综合检测试剂盒及应用 | |
CN101386889A (zh) | 一种amacr基因的原位杂交检测试剂盒及其检测方法和应用 | |
CN101363046A (zh) | 一种广谱性癌症原位杂交检测试剂盒及其检测方法和应用 | |
CN101363047A (zh) | 一种ttf1基因的原位杂交检测试剂盒及其检测方法和应用 | |
CN101363051A (zh) | 一种galectin-3基因的原位杂交检测试剂盒及其检测方法和应用 | |
CN101469350B (zh) | 一种前列腺癌症早期的综合检测试剂盒及检测方法和应用 | |
CN101469348B (zh) | 一种前列腺癌症早期的原位杂交检测试剂盒及其检测方法和应用 | |
CN101988095A (zh) | 一种scca1基因的原位杂交检测试剂盒及其检测方法和应用 | |
CN101363050B (zh) | 一种cd326基因的原位杂交检测试剂盒及其检测方法和应用 | |
CN101469349A (zh) | 一种肺癌原位杂交综合检测试剂盒及检测方法和应用 | |
CN101429542A (zh) | 一种vmp1基因的原位杂交检测试剂盒及其检测方法和应用 | |
CN101363048B (zh) | 一种nkx2-8基因的原位杂交检测试剂盒及其检测方法和应用 | |
CN101386888B (zh) | 一种Evi-1基因的原位杂交检测试剂盒 | |
CN101429548A (zh) | Dlk1基因核酸原位杂交检测试剂盒和检测方法和应用 | |
CN101993927A (zh) | 一种lamb1基因的原位杂交检测试剂盒及其检测方法和应用 | |
CN101386890B (zh) | 一种lamin a基因的原位杂交检测试剂盒及其检测方法和应用 | |
CN101363053A (zh) | 一种tMK基因的原位杂交检测试剂盒及其检测方法和应用 | |
CN101363049A (zh) | 一种癌症早期转移的原位杂交检测试剂盒及其检测方法和应用 | |
CN101993917A (zh) | 一种cdc2基因的原位杂交检测试剂盒及其检测方法和应用 | |
CN101429554B (zh) | Hccr基因核酸原位杂交检测试剂盒和检测方法和应用 | |
CN101429551B (zh) | Hmg-1基因核酸原位杂交检测试剂盒和检测方法与应用 | |
CN101429555A (zh) | 一种胰腺癌症早期的原位杂交检测试剂盒及其检测方法和应用 | |
CN101328499B (zh) | 一种RhoGDI2基因的原位杂交检测试剂盒及其检测方法和应用 | |
CN101993919A (zh) | 一种pd-ecgf基因的原位杂交检测试剂盒及其检测方法和应用 | |
CN101993944A (zh) | 一种aldh1基因的原位杂交检测试剂盒及其检测方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SUZHOU FUYING GENE TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: RUIQU BIOTECHNOLOGY (SHANGHAI) CO., LTD. Effective date: 20110429 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201108 ROOM 426, BUILDING 4, NO. 728, GUANGHUA ROAD, MINHANG DISTRICT, SHANGHAI TO: 215132 ROOM 307, BUILDING A2, BIOBAY, NO. 218, XINGHU STREET, SUZHOU INDUSTRIAL PARK |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110429 Address after: 215132 Suzhou Industrial Park BioBAY Xinghu Street No. 218 building A2 room 307 Applicant after: Suzhou Fuying Gene Technology Co.,Ltd. Address before: 201108 room 4, building 728, Guanghua Road, 426, Shanghai, Minhang District Applicant before: Ruiqu Biotechnology (Shanghai) Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: LI XUEYING Free format text: FORMER OWNER: SUZHOU FUYING GENE TECHNOLOGY CO., LTD. Effective date: 20150727 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150727 Address after: 704, room 2, unit 1, B District, Oriental Pearl District, Liandu District, Zhejiang, Lishui 323000, China Patentee after: Li Xueying Address before: Suzhou Industrial Park BioBAY Xinghu Street No. 218 building A2 room 307 Patentee before: Suzhou Fuying Gene Technology Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20201116 Address after: Room 631, No. 318, Taizhou Road, Zhejiang Province Patentee after: Taizhou hehe Biotechnology Co., Ltd Address before: 704, room 2, unit 1, B District, Oriental Pearl District, Liandu District, Zhejiang, Lishui 323000, China Patentee before: Li Xueying |
|
TR01 | Transfer of patent right |